
Search Clinical Trials
Sponsor Condition of Interest |
---|
DeciPHer-ILD: a Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated with Inter1
United Therapeutics
Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Pulmonary Hypertension
Interstitial Lung Disease
This is a prospective, non-interventional, multicenter, registry of patients with
pulmonary hypertension associated with interstitial lung disease (PH-ILD). expand
This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Type: Observational Start Date: Jan 2025 |
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants with Progressive Pulmona1
Avalyn Pharma Inc.
Progressive Pulmonary Fibrosis
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and
efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of
care in participants with PPF over 52 weeks. expand
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks. Type: Interventional Start Date: Apr 2024 |
A Safety Study of SGN-35C in Adults With Advanced Cancers
Seagen Inc.
Hodgkin Disease
Lymphoma, T-Cell, Peripheral
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Large-Cell, Anaplastic
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood
cells that fight infection. There are several types of lymphoma. This study will enroll
people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or
diffuse large B cell lymphoma (DLBC1 expand
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL). This clinical trial uses a drug called SGN-35C . The study drug is in testing and has not been approved for sale. This is the first time SGN -35C will be used in people. This study will test the safety of SGN-35C in participants with lymphoma. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have three parts. Parts A and B of the study will find out the best dose and dosing schedule for SGN-35C. Part C will use the dose found in parts A and B to find out how safe SGN-35C is and if it works to treat select lymphomas. Type: Interventional Start Date: May 2024 |
Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne1
Sardocor Corp.
DMD-Associated Dilated Cardiomyopathy
This research study is testing whether an experimental drug, called SRD-001, is safe and
helps the weakened heart of patients with Duchenne muscular dystrophy (DMD) regain its
ability to effectively pump blood to the rest of the body. SRD-001 is a form of gene
therapy. The goal of SRD-001 gene ther1 expand
This research study is testing whether an experimental drug, called SRD-001, is safe and helps the weakened heart of patients with Duchenne muscular dystrophy (DMD) regain its ability to effectively pump blood to the rest of the body. SRD-001 is a form of gene therapy. The goal of SRD-001 gene therapy is to provide the heart muscle cells with extra copies of the SERCA2a gene so that they can produce more SERCA2a protein to help the heart muscle cells squeeze/contract better. Researchers will compare SRD-001 treated participants with no-treatment participants; all participants will continue to take their current heart medications. All participants will be followed very closely for 2 years and undergo cardiac magnetic resonance imaging of their heart at baseline, year 1 and year 2 along with assessment of upper limb function and lung function. After the 2 years of close follow-up, all participants will roll over into long-term follow-up where they will be called biannually for information on their current medical status. Type: Interventional Start Date: Oct 2024 |
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NovoCure GmbH
Metastatic Non-small Cell Lung Cancer
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using
TTFields, delivered by the NovoTTF-200T device, concomitantly administered with
pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell
lung cancer that has spread to other parts1 expand
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer. Type: Interventional Start Date: Jul 2024 |
Lung Transplant READY CF 2: A Multi-site RCT
University of Washington
Cystic Fibrosis
Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF).
In the United States, more people with CF and low lung function die each year than
undergo lung transplant. More than half of people with CF who die without a lung
transplant were never referred for considerat1 expand
Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). In the United States, more people with CF and low lung function die each year than undergo lung transplant. More than half of people with CF who die without a lung transplant were never referred for consideration. Patient preference not to undergo lung transplant may account for 25-40% of decisions to defer referral. Rates of death without transplant are higher for people with CF who are members of marginalized communities, including those with Black race, Hispanic ethnicity, or low socioeconomic status. Increasing awareness of lung transplant among people with CF, and promoting understanding of the risks and benefits of transplant, can potentially reduce the number of people with CF who die without a lung transplant. The CF Foundation (CFF) lung transplant referral guidelines were developed to optimize the timing of referral for lung transplant. These guidelines recommend annual conversations with people with CF once their forced expiratory volume in one second (FEV1) is <50% predicted. Considering lung transplant as a treatment option before it is medically needed will allow more time to learn about lung transplant and address any barriers to lung transplant that may exist. Investigators are interested in understanding how people with CF use lung transplant educational resources and how one prepares for having discussions and/or making decisions about lung transplant as a treatment option for advanced CF. The purpose of this study is to test whether a research website improves patient preparedness for discussions about lung transplant. Investigators also aim to understand whether there are unique factors that affect people with CF from communities with decreased access to transplant ("communities of concern"). Study involvement will span 6 months and study activities will involve the following: - Four Zoom research sessions (15-30 minutes each) - Survey assessments - Access to a research website that contains educational resources about lung transplant - Audio recording of a routine CF clinic visit to determine if and how lung transplant is discussed between a participant and his/her/their CF doctor Type: Interventional Start Date: Sep 2023 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiop1
Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of
BMS-986278 in participants with Idiopathic Pulmonary Fibrosis. expand
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis. Type: Interventional Start Date: Sep 2023 |
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Par1
Iovance Biotherapeutics, Inc.
Metastatic Melanoma
Unresectable Melanoma
Melanoma
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study
to assess the efficacy and safety of lifileucel in combination with pembrolizumab
compared with pembrolizumab alone in participants with untreated, unresectable or
metastatic melanoma. Participants randomized to1 expand
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period. Type: Interventional Start Date: Mar 2023 |
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
Procyrion
Heart Failure
Cardiorenal Syndrome
Cardio-Renal Syndrome
ADHF
Heart Failure, Systolic
Aortix is a circulatory support device for chronic heart failure patients on medical
management who have been hospitalized for acute decompensated heart failure (ADHF) and
have persistent congestion despite usual medical therapy.
Eligible ADHF patients with diuretic resistance (irrespective of eje1 expand
Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management. Type: Interventional Start Date: Aug 2023 |
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Solid Tumor
This is an open-label study. This means that people in this study and clinic staff will
know that they will receive ASP3082. The study aims to check how safe and well-tolerated
ASP3082 is for people with advanced solid tumors that have a specific mutation called
KRAS G12D.
This study will be in 21 expand
This is an open-label study. This means that people in this study and clinic staff will know that they will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D. This study will be in 2 parts. In Part 1, different small groups of people will receive lower to higher doses of ASP3082 by itself, or together with cetuximab. Any medical problems will be recorded at each dose. This is done to find suitable doses of ASP3082, by itself or together with cetuximab, to use in Part 2 of the study. The first group will receive the lowest dose of ASP3082. A medical expert panel will check the results from this group and decide if the next group can receive a higher dose of ASP3082. The panel will do this for each group until all groups have received ASP3082 (by itself or together with cetuximab) or until suitable doses have been selected for Part 2. In Part 2, ASP3082 will be given in by itself, or in combination with other chemotherapy agents. Study treatments will be given through a vein. This is called an infusion. Each treatment cycle is 21 or 28 days long. They will continue treatment until: they have medical problems from the treatment they can't tolerate; their cancer gets worse; they start other cancer treatment; or they ask to stop treatment. Type: Interventional Start Date: Jun 2022 |
A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome
Tetra Discovery Partners
Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male
Adults (Aged 18 to 45) with Fragile X Syndrome expand
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) with Fragile X Syndrome Type: Interventional Start Date: Nov 2022 |
4D-710 in Adult Patients With Cystic Fibrosis
4D Molecular Therapeutics
Cystic Fibrosis Lung
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational
gene therapy in adults with cystic fibrosis. expand
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis. Type: Interventional Start Date: Mar 2022 |
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone1
National Cancer Institute (NCI)
Metastatic Bladder Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Refractory Bladder Urothelial Carcinoma
Refractory Urothelial Carcinoma
Stage IV Bladder Cancer AJCC v8
This phase III trial compares the usual chemotherapy treatment to eribulin plus
gemcitabine in treating patients with urothelial cancer that has spread from where it
first started (primary site) to other places in the body (metastatic). Chemotherapy
drugs, such as eribulin, gemcitabine, docetaxel,1 expand
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer. Type: Interventional Start Date: Jun 2021 |
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
GT Medical Technologies, Inc.
Brain Tumor, Recurrent
Brain Tumor
Brain Tumor, Primary
Brain Tumor - Metastatic
Brain Tumor, Adult: Glioblastoma
The objectives of this registry study are to evaluate real-world clinical outcomes and
patient reported outcomes that measure the effectiveness and safety of STaRT. expand
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT. Type: Observational [Patient Registry] Start Date: Sep 2020 |
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell1
Janssen Research & Development, LLC
Multiple Myeloma
The purpose of this study is to evaluate the overall minimal residual disease (MRD)
negative rate of participants who receive JNJ-68284528. expand
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528. Type: Interventional Start Date: Nov 2019 |
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Ag1
Celgene
Lymphoma, Non-Hodgkin
The purpose of this study is to evaluate the safety, tolerability, and preliminary
efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants
with relapsed or refractory non-Hodgkin's lymphomas. expand
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas. Type: Interventional Start Date: May 2019 |
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cance1
National Cancer Institute (NCI)
Bladder Adenocarcinoma
Bladder Clear Cell Adenocarcinoma
Bladder Mixed Adenocarcinoma
Bladder Neuroendocrine Carcinoma
Bladder Small Cell Neuroendocrine Carcinoma
This phase II trial studies how well cabozantinib works in combination with nivolumab and
ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from
where it first started (primary site) to other places in the body. Cabozantinib may stop
the growth of tumor cells by bl1 expand
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone. Type: Interventional Start Date: May 2019 |
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Ref1
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Recurrent B Acute Lymphoblastic Leukemia
Refractory B Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in
treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly
diagnosed, has come back, or does not respond to treatment. Immunotherapy with monoclonal
antibodies, such as inotuzumab ozog1 expand
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back, or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as inotuzumab ozogamicin and blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Type: Interventional Start Date: May 2019 |
Sleep Health Enhancement in Midlife Adults
University of Kansas Medical Center
Sleep Health
Midlife Adults
Despite the strong links between sleep and AD, a sleep health enhancement has yet to be
targeted in mid-life adults (45-64 years old) to delay or prevent AD. An intervention
aimed at enhancing sleep health is a critical opportunity for primary prevention to
potentially delay the onset of AD. The ob1 expand
Despite the strong links between sleep and AD, a sleep health enhancement has yet to be targeted in mid-life adults (45-64 years old) to delay or prevent AD. An intervention aimed at enhancing sleep health is a critical opportunity for primary prevention to potentially delay the onset of AD. The objective of the proposed study is to develop and assess the feasibility, acceptability, and treatment effect of a comprehensive sleep health intervention (SHI) on improving sleep health in mid-life adults Type: Interventional Start Date: Feb 2024 |
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With S1
Cytokinetics
Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
This clinical trial will study the effects of aficamten (versus placebo) on the quality
of life, exercise capacity, and clinical outcomes of patients with non-obstructive
hypertrophic cardiomyopathy. expand
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy. Type: Interventional Start Date: Aug 2023 |
Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future
International Consortium of Circulatory Assist Clinicians
LVAD
Frailty
GI Bleed
Right Heart Failure
Infections
Durable left ventricular assist devices (dLVAD) have been increasingly utilized since the
mid to late 1990s, with an uptick of utility starting in 2010 following expanded
indications for therapy to not only include a bridge to transplantation strategy, but
also for those individuals who suffer from1 expand
Durable left ventricular assist devices (dLVAD) have been increasingly utilized since the mid to late 1990s, with an uptick of utility starting in 2010 following expanded indications for therapy to not only include a bridge to transplantation strategy, but also for those individuals who suffer from advanced heart failure (HF) and do not qualify for cardiac transplantation. Despite the decreasing size of the newest generation devices leading to a lessened occurrence of adverse events, bleeding and infection still remain a concern for clinicians, as well as a general lack of predictability towards adverse events in individuals with a dLVAD in place. There is a lack of description in the literature currently, regarding the interface between what the pump data provides and what is seen in clinical practice. There also is little known about the effects of what is provided in the pump data, in correlation to quality-of-life following dLVAD implantation. Therefore, the purpose of this study is to prospectively analyze normal and abnormal pump data through pump operations such as suction events, low flow alarms as well as other adventitious alarms, PI events and power cable disconnects greater than 20 seconds, from the HeartMate 3 ® dLVAD in order to clinically correlate this data to quality of life, frailty and other various medical conditions and adverse events as defined by the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs). This will be achieved through two aims: 1) Evaluate the effectiveness of dLVAD pump operations data on clinical practice application (quality of life, frailty and various medical conditions, and adverse events such as GIB, RHF, infection, hypertension, arrhythmias and stroke); and 2) Evaluate correlations and relationships of longitudinal normal and abnormal dLVAD pump operations data, to demographic and clinical variables. This study is the first study to evaluate HeartMate 3 ® dLVAD pump operations data over time for effectiveness in the clinical practice. Type: Observational Start Date: Oct 2023 |
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
New York State Psychiatric Institute
Autism Spectrum Disorder
This Phase 2 study examines the safety, tolerability, and preliminary efficacy of
pimavanserin in individuals with Autism Spectrum Disorder. Male or female participants
aged 16 to 40 years of age will be randomized to receive single doses of either placebo
or pimavanserin in this randomized, placeb1 expand
This Phase 2 study examines the safety, tolerability, and preliminary efficacy of pimavanserin in individuals with Autism Spectrum Disorder. Male or female participants aged 16 to 40 years of age will be randomized to receive single doses of either placebo or pimavanserin in this randomized, placebo-controlled, cross-over designed study, followed by open label extension. Type: Interventional Start Date: Mar 2025 |
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneu1
Janssen Research & Development, LLC
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab
compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating
polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A. expand
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A. Type: Interventional Start Date: Sep 2022 |
Combined Exercise Trial
University of Kansas Medical Center
Healthy Aging
The number of older Americans will double in the next 4 decades to nearly 90 million,
placing an unprecedented financial and resource burden on the health care system.
Exercise has clear and demonstrable physical benefits, but a more precise understanding
of how exercise supports cognitive function1 expand
The number of older Americans will double in the next 4 decades to nearly 90 million, placing an unprecedented financial and resource burden on the health care system. Exercise has clear and demonstrable physical benefits, but a more precise understanding of how exercise supports cognitive function is essential. Demonstrating definitively that exercise as recommended by public health entities has benefits for cognition would have enormous public health implications, encourage the public to adapt more active lifestyles, and stimulate the development of effective exercise delivery programs. Type: Interventional Start Date: Oct 2021 |
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
GT Medical Technologies, Inc.
Brain Metastases
This trial will be a randomized controlled study comparing the efficacy and safety of
intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following
metastatic tumor resection which is the current standard of care. expand
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care. Type: Interventional Start Date: Apr 2021 |
- Previous
- Next